Zacks: Analysts Expect InflaRx (NASDAQ:IFRX) Will Announce Earnings of -$0.25 Per Share

Wall Street brokerages expect InflaRx (NASDAQ:IFRX) to announce earnings of ($0.25) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for InflaRx’s earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.23). InflaRx reported earnings per share of ($0.42) during the same quarter last year, which would indicate a positive year-over-year growth rate of 40.5%. The company is expected to issue its next earnings results on Thursday, July 29th.

According to Zacks, analysts expect that InflaRx will report full-year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.13) to ($0.88). For the next financial year, analysts forecast that the firm will report earnings of ($1.04) per share, with EPS estimates ranging from ($1.24) to ($0.87). Zacks’ EPS averages are a mean average based on a survey of analysts that follow InflaRx.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Wednesday, May 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05.

Several research firms have issued reports on IFRX. Raymond James lowered their price objective on shares of InflaRx from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Thursday, May 13th. Zacks Investment Research raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group lowered their price objective on shares of InflaRx from $3.50 to $2.80 and set an “underperform” rating for the company in a research report on Thursday, May 13th. SVB Leerink reaffirmed a “buy” rating and issued a $6.00 price target on shares of InflaRx in a research report on Wednesday, May 19th. Finally, HC Wainwright lowered their price target on shares of InflaRx from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, March 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $8.33.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Group AG raised its stake in shares of InflaRx by 235.5% during the 1st quarter. UBS Group AG now owns 6,529 shares of the company’s stock worth $25,000 after acquiring an additional 4,583 shares in the last quarter. BlackRock Inc. increased its stake in InflaRx by 77.7% during the 1st quarter. BlackRock Inc. now owns 7,419 shares of the company’s stock valued at $29,000 after purchasing an additional 3,245 shares in the last quarter. Pacifica Partners Inc. increased its stake in InflaRx by 247.2% during the 1st quarter. Pacifica Partners Inc. now owns 12,585 shares of the company’s stock valued at $48,000 after purchasing an additional 8,960 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in InflaRx during the 4th quarter valued at approximately $87,000. Finally, Marquette Asset Management LLC acquired a new position in InflaRx during the 2nd quarter valued at approximately $99,000. Hedge funds and other institutional investors own 33.53% of the company’s stock.

Shares of IFRX stock traded down $0.02 during trading hours on Friday, reaching $2.65. 142,135 shares of the stock were exchanged, compared to its average volume of 136,288. The company has a market cap of $114.56 million, a price-to-earnings ratio of -2.02 and a beta of 0.47. InflaRx has a 12-month low of $2.42 and a 12-month high of $6.88. The stock’s 50-day moving average is $2.94.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases.

Read More: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on InflaRx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for InflaRx (NASDAQ:IFRX)

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.